Risk Minimization of Antibody–Drug Conjugates in Oncology: A Review
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Risk Minimization of Antibody–Drug Conjugates in Oncology: A Review
Authors
Keywords
-
Journal
DRUG SAFETY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-05-14
DOI
10.1007/s40264-021-01069-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- First-in-Human Phase 1 Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients With Relapsed and Refractory Multiple Myeloma
- (2020) Ravi Vij et al. CLINICAL CANCER RESEARCH
- UPLC-based assay to assess the hydrophobicity of Antibody-Drug Conjugate (ADC) payloads
- (2020) Ilona Pysz et al. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES
- LBA17 ASCENT: A randomized phase III study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in patients (pts) with previously treated metastatic triple-negative breast cancer (mTNBC)
- (2020) A. Bardia et al. ANNALS OF ONCOLOGY
- Belantamab Mafodotin: First Approval
- (2020) Anthony Markham DRUGS
- Safety and Tolerability of Antibody-Drug Conjugates in Cancer
- (2019) Anna Wolska-Washer et al. DRUG SAFETY
- Antibody-Drug Conjugate-Based Therapeutics: State of the Science
- (2019) Michael J Birrer et al. JNCI-Journal of the National Cancer Institute
- Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long‐term survival follow‐up from the randomized, phase 3 INO‐VATE study
- (2019) Hagop M. Kantarjian et al. CANCER
- Antibody–Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index
- (2019) Steven Coats et al. CLINICAL CANCER RESEARCH
- Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates
- (2019) Prathap Kumar Mahalingaiah et al. PHARMACOLOGY & THERAPEUTICS
- Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy
- (2019) Jonathan E. Rosenberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small Cell Lung Cancer: Results From the Phase II TRINITY Study
- (2019) Daniel Morgensztern et al. CLINICAL CANCER RESEARCH
- CRISPR-Cas9 screens identify regulators of antibody–drug conjugate toxicity
- (2019) C. Kimberly Tsui et al. Nature Chemical Biology
- Trastuzumab-Induced Cardiomyopathy
- (2019) Rachel Barish et al. CARDIOLOGY CLINICS
- An FDA oncology analysis of toxicities associated with PBD-containing antibody-drug conjugates
- (2019) Haleh Saber et al. REGULATORY TOXICOLOGY AND PHARMACOLOGY
- Safety Analysis of Brentuximab Vedotin from the Phase III AETHERA Trial in Hodgkin Lymphoma in the Post-Transplant Consolidation Setting
- (2018) Auayporn Nademanee et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Fate of Antibody-Drug Conjugates in Cancer Cells
- (2018) Cécile Chalouni et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- OUP accepted manuscript
- (2018) NEURO-ONCOLOGY
- Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
- (2018) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Brief Introduction to Antibody–Drug Conjugates for Toxicologic Pathologists
- (2018) Lars Mecklenburg TOXICOLOGIC PATHOLOGY
- From Anthramycin to Pyrrolobenzodiazepine (PBD)-Containing Antibody-Drug Conjugates (ADCs)
- (2016) Julia Mantaj et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Antibody drug conjugates: lessons from 20 years of clinical experience
- (2016) A. W. Tolcher ANNALS OF ONCOLOGY
- Cardiotoxic effects of the novel anti-ErbB2 agent ado trastuzumab emtansine
- (2016) R.V. Iaffaioli et al. ANNALS OF ONCOLOGY
- Trastuzumab cardiotoxicity: from clinical trials to experimental studies
- (2016) Balazs T Nemeth et al. BRITISH JOURNAL OF PHARMACOLOGY
- The US Food and Drug Administration’s Risk Evaluation and Mitigation Strategy (REMS) Program – Current Status and Future Direction
- (2016) Jasmanda Wu et al. CLINICAL THERAPEUTICS
- Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial
- (2016) Sergio Amadori et al. JOURNAL OF CLINICAL ONCOLOGY
- Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates
- (2016) Heather Donaghy mAbs
- Results of a Phase II Trial of Brentuximab Vedotin for CD30+Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis
- (2015) Madeleine Duvic et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study
- (2015) Maria Corinna A Palanca-Wessels et al. LANCET ONCOLOGY
- Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
- (2010) Anas Younes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase I Study of Sequence-Selective Minor Groove DNA Binding Agent SJG-136 in Patients with Advanced Solid Tumors
- (2009) D. Hochhauser et al. CLINICAL CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started